Biolase regains position on Nasdaq listing: 4 things to know

After failing to meet Nasdaq's listing qualifications, Biolase was removed from being listed on the Nasdaq Capital Market, later regaining the listing.

Here are four things to know:

1. Biolase received the notice it failed to meet Nasdaq's $1 per share minimum bid price Aug. 9, 2017. Nasdaq informed the dental laser developer its common stock failed to maintain the minimum for the previous 30 consecutive business days.

2. Earlier in May, Biolase executed a 1-for-5 reverse stock split to help regain compliance with Nasdaq.

3. Biolase received a letter from Nasdaq's listing qualifications department the following day stating the company met the minimum bid price for 10 consecutive days.

4. The company is now in compliance with listing rule 5550(a)(2) and the issue is closed with Nasdaq.

More articles on dental:
Henry Schein CEO delivers commencement speech to 3 graduating classes: 3 takeaways
Delta Dental, Bright Side Dental & Orthodontic & more: 3 dental companies making headlines
Woman receives 6-month sentence for role in 8-year dental practice embezzlement scheme

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

Featured Webinars

Featured Whitepapers

Featured Podcast